Loading
Led OVHIPEC-1, the trial that showed heated intraperitoneal chemotherapy at surgery extends survival in ovarian cancer.
Willemien van Driel was principal investigator of OVHIPEC-1, the Dutch randomised trial showing that adding hyperthermic intraperitoneal cisplatin to interval cytoreductive surgery improves recurrence-free and overall survival in stage III ovarian cancer, the first level-one evidence for HIPEC in the disease. She leads OVHIPEC-2 in the primary surgery setting.
| Title | Journal | Year |
|---|---|---|
| Hyperthermic intraperitoneal chemotherapy in ovarian cancer (OVHIPEC-1) | NEJM | 2018 |
| Overall survival after hyperthermic intraperitoneal chemotherapy for ovarian cancer: 10-year follow-up of OVHIPEC-1 | Lancet Oncology | 2023 |
Shares OVHIPEC-1, HIPEC / PIPAC (intraperitoneal chemotherapy), Ovarian cancer.
Shares Ovarian cancer and the tags ovarian, surgery.
Shares Ovarian cancer and the tags ovarian, surgery.
Shares HIPEC / PIPAC (intraperitoneal chemotherapy), Ovarian cancer.
Shares HIPEC / PIPAC (intraperitoneal chemotherapy), Ovarian cancer.
Shares Ovarian cancer and the tag ovarian.
Shares Ovarian cancer and the tag surgery.
Shares Ovarian cancer and the tag ovarian.